Full text

Turn on search term navigation

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

The success rate of establishing human cancer cell lines is not satisfactory and the established cell lines often do not preserve the molecular and histological features of the original tissues. In this study, we developed a novel culture method which can support proliferation of almost all primary epithelial ovarian cancer cells, as well as primary normal human oviductal epithelial cells. Cancer cells from fresh or frozen specimens were enriched by the anti-EpCAM antibody-conjugated magnetic beads, plated on Matrigel-coated plate and cultivated under the optimized culture conditions. Seventeen newly established ovarian cancer cell lines, which included all four major histotypes of ovarian cancer, were confirmed to express histotype-specific markers in vitro. Some of the cell lines from all the four histotypes, except mucinous type, generated tumors in immune-deficient mice and the xenograft tumor tissues recapitulated the corresponding original tissues faithfully. Furthermore, with poorly tumorigenic cell lines including mucinous type, we developed a novel xenograft model which could reconstruct the original tissue architecture through forced expression of a set of oncogenes followed by its silencing. With combination of the novel culture method and cell-derived xenograft system, virtually every epithelial ovarian cancer can be reconstituted in mice in a timely fashion.

Details

Title
An Ex-Vivo Culture System of Ovarian Cancer Faithfully Recapitulating the Pathological Features of Primary Tumors
Author
Farhana Ishrat Ghani 1 ; Dendo, Kasumi 1 ; Watanabe, Reiko 2 ; Yamada, Kenji 3 ; Yoshimatsu, Yuki 3 ; Yugawa, Takashi 3 ; Nakahara, Tomomi 3   VIAFID ORCID Logo  ; Tanaka, Katsuyuki 3 ; Yoshida, Hiroshi 4 ; Yoshida, Masayuki 4 ; Ishikawa, Mitsuya 5 ; Goshima, Naoki 6 ; Kato, Tomoyasu 5 ; Kiyono, Tohru 1 

 Division of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute, Tokyo 104-0045, Japan; Department of Cell Culture Technology, National Cancer Center Research Institute, Tokyo 104-0045, Japan 
 Department of Cell Culture Technology, National Cancer Center Research Institute, Tokyo 104-0045, Japan 
 Division of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute, Tokyo 104-0045, Japan 
 Pathology Division, National Cancer Center Hospital, Tokyo 104-0045, Japan 
 Department of Gynecology, National Cancer Center Hospital, Tokyo 104-0045, Japan 
 Molecular Profiling Research Center for Drug Discovery, National Institute of Advanced Industrial Science and Technology, 2-4-7 Aomi, Koto-ku, Tokyo 135-0064, Japan 
First page
644
Publication year
2019
Publication date
2019
Publisher
MDPI AG
e-ISSN
20734409
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2548331764
Copyright
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.